{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-013037","form_type":"8-K","ticker":"ELTP","cik":"0001053369","company_name":"ELITE PHARMACEUTICALS INC /NV/","filed_at":"2023-04-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.786295+00:00","generated_at":"2026-06-16T22:07:44.935743+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Elite Pharmaceuticals files ANDA for generic antimetabolite; $42M market","bullets":["Filed Abbreviated New Drug Application with FDA for an undisclosed generic antimetabolite drug.","IQVIA reports annual sales of $42M for the generic market of this product (12 months ending Dec 2022).","Elite is a specialty pharma developing niche generics; facility in Northvale, NJ."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-013037","json":"https://secwatch.observer/filing/0001493152-23-013037.json","markdown":"https://secwatch.observer/filing/0001493152-23-013037.md","text":"https://secwatch.observer/filing/0001493152-23-013037.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053369/000149315223013037/0001493152-23-013037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053369/000149315223013037/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T22:07:44.935743+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}